Ronald Berenson
Gründer bei KitoTech Medical, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Paul McBarron | M | 63 | 22 Jahre | |
Spiro Rombotis | M | 65 | 27 Jahre | |
Christopher Henney | M | 83 | 18 Jahre | |
Larry Hayes | M | - |
KitoTech Medical, Inc.
KitoTech Medical, Inc. Medical SpecialtiesHealth Technology KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA. | 1 Jahre |
Stewart D. Chipman | M | - |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
Syed Zaidi | M | - |
Fe3 Medical, Inc.
Fe3 Medical, Inc. Medical SpecialtiesHealth Technology Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX. | - |
Mir Imran | M | 67 |
Fe3 Medical, Inc.
Fe3 Medical, Inc. Medical SpecialtiesHealth Technology Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX. | 16 Jahre |
Paul Leung | M | - |
KitoTech Medical, Inc.
KitoTech Medical, Inc. Medical SpecialtiesHealth Technology KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA. | - |
Ross Davidson | M | - |
Fe3 Medical, Inc.
Fe3 Medical, Inc. Medical SpecialtiesHealth Technology Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX. | - |
Carl J. March | M | - |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
David Cosman | M | - |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
Frederick Telling | M | 73 |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
Philip Morgan | M | - |
Fe3 Medical, Inc.
Fe3 Medical, Inc. Medical SpecialtiesHealth Technology Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX. | - |
James A. Bianco | M | 67 |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
Mark Sieczkarek | M | 69 |
Fe3 Medical, Inc.
Fe3 Medical, Inc. Medical SpecialtiesHealth Technology Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX. | 9 Jahre |
Wayne I. Roe | M | 73 |
Fe3 Medical, Inc.
Fe3 Medical, Inc. Medical SpecialtiesHealth Technology Fe3 Medical, Inc. develops a transdermal therapy for iron deficiency anemia. It offers a disposable transdermal patch that delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. The company was founded by Mir A. Imran in 2008 and is headquartered in San Antonio, TX. | - |
Jack W. Singer | M | 81 |
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | - |
Patrick Edward Fry | M | 66 |
KitoTech Medical, Inc.
KitoTech Medical, Inc. Medical SpecialtiesHealth Technology KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA. | 4 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
David C. U'Prichard | M | 75 | 16 Jahre | |
John Brzezenski | M | - |
KitoTech Medical, Inc.
KitoTech Medical, Inc. Medical SpecialtiesHealth Technology KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA. | 1 Jahre |
Judy Chiao | M | 64 | 17 Jahre | |
John Banham | M | 83 | 14 Jahre | |
David Glover | M | - | - | |
Dan Spiegelman | M | 65 | 8 Jahre | |
Stephen Neal Wertheimer | M | 73 | - | |
Edward F. Kenney | M | 79 |
CellPro, Inc.
| 1 Jahre |
Joann M. Reiter | F | 67 |
CellPro, Inc.
| 5 Jahre |
Robert Nelsen | M | 60 | - | |
Robert Westwood | M | - | - | |
Robert Jackson | M | 64 | 6 Jahre | |
Kathi Cordova | F | - | - | |
Gill Christie | F | - | - | |
Pierre Legault | M | 63 | 3 Jahre | |
David Lane | M | - | - | |
Susan Davis | M | 59 | 18 Jahre | |
Michael Craig Gruber | M | - |
KitoTech Medical, Inc.
KitoTech Medical, Inc. Medical SpecialtiesHealth Technology KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA. | 2 Jahre |
Carlo Rago | M | - |
DMD Therapeutics, Inc.
DMD Therapeutics, Inc. BiotechnologyHealth Technology DMD Therapeutics, Inc. develops novel therapeutics for DMD and other muscular dystrophies. The company was founded by Carlo Rago and Ronald Berenson in 2016 and is headquartered in Seattle, WA. | - |
Marco Rolandi | M | - |
KitoTech Medical, Inc.
KitoTech Medical, Inc. Medical SpecialtiesHealth Technology KitoTech Medical, Inc. operates as a medical device company which develops medical products based on its proprietary micro staple technology platform. It specializes in wound closure, patient care, emergency laceration, surgery, skin closure device, and biotechnology. The company was founded by Ronald J. Berenson and Marco Rolandi in 2013 and is headquartered in Seattle, WA. | - |
Robert A. Vandervelde | M | 61 |
CellPro, Inc.
| 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 39 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Ronald Berenson
- Persönliches Netzwerk